Marco Meglio

In the phase 3 OCARINA 2 trial, subcutaneous ocrelizumab was non-inferior to intravenous infusion based on concentration levels in the blood, as well as comparable efficacy on relapses and brain lesions.

The FDA approval of Medtronic’s spinal cord stimulator makes it the first on the market to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real time for chronic pain.

In comparison to previously approved treatments like satralizumab and inebilizumab, ravulizumab-treated patients performed significant better on outcomes of first relapse and time to first relapse.

Ravulizumab reduced NfL levels in cerebrospinal fluid and serum whereas eculizumab showed no change in NfL when compared with placebo.

The professor of neurology and pharmacology at the University of California Davis Health Medical Center gave commentary on the FDA approval of Aquestive Therapeutics’ buccal film in pediatric patients with intermittent, stereotypic episodes of frequent seizure activity.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on primary progressive aphasia.

Stephen Samples, MD, chair of Allegheny Health Network’s department of neurology, gave commentary towards the AHS’s recent statement paper addressing CGRP-targeting therapies as a first-line option for preventive migraine.

Satralizumab, an IL-6 receptor inhibitor, shows promise in reducing infection rates compared to historical data.

After 2 years of treatment, EDG-5506, otherwise known as sevasemten, was well-tolerated, with rapid and sustained decreases in biomarkers of muscle damage.

The head of neurosciences at the Jane and John Justin Neurosciences Center of Cook Children’s Medical Center provided commentary on the need to properly diagnose Lennox-Gastaut syndrome and the negative downstream impacts of misdiagnosis or underdiagnosing patients.

Lauren Seidman, a second-year medical student at NYU Langone’s Grossman School of Medicine, provided perspective on a poster at AAN 2024 highlighting the use of binocular visual function testing in Alzheimer disease.

Between those with NMOSD and NAION, the data showed differences in disc edema, peripapillary nerve fiber layer thickening, vision loss, and the symptoms that preceded vision loss.

Using the Wechsler Adult Intelligence Scale Fourth Edition (WAIS-IV) Coding Test score, SAGE-718 failed to distinguish itself from placebo.

Foralumab's anti-CD3 mechanism modulates T cell function, offering potential benefits for the challenging-to-treat na-SPMS patients.

Mark Bain, MD, a neurosurgeon at Cleveland Clinic’s Cerebrovascular Center, provided commentary on the ENRICH trial, a positive study of minimally invasive removal of intracerebral hemorrhage.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the sleep disorders.

Tavapadon's phase 3 success complements ongoing monotherapy trials, addressing the need for effective and well-tolerated PD therapies.

The research grant aims to diversify Friedreich ataxia treatments, addressing challenges in trial design and therapeutic strategies for this condition.

Patients experienced improvements in ON/OFF time and motor function, with favorable tolerability, paving the way for a phase 2 trial.

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Ian Kremer. [LISTEN TIME: 35 minutes]

Across 2, phase 3 studies, fremanezumab provided significant effects on monthly migraine days, regardless of whether patients were obese or not.

Even when combining both adult and pediatric patients, diazepam nasal spray administered within 5 minutes of a seizure led to quicker seizure termination.

Investigators found no trends in amyloid-imaging abnormality rates based on centile tertile levels for lecanemab-treated patients.

Patients treated with ALZ-801 showed improvements in cognition, reduced brain atrophy, and maintained dementia rating stages.

Over 2, phase 3 studies, brexpiprazole-treated patients demonstrated greater response rates across various levels on the Cohen-Mansfield Agitation Index and Clinical Impression Scale-Improvement assessment.

Combination of atogepant and ubrogepant resulted in minimal adverse events, and were safe and well-tolerated over a 12-week period.

Results showed consistent reductions in monthly migraine days over 48 weeks, with a favorable safety profile observed.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the American Academy of Neurology Annual Meeting.

Patients on riliprubart demonstrated improvements on several measures of disability and impairment, including the INCAT, I-RODS, MRC-SS, and grip strength.

Patients with first MS symptoms less than 3 years prior to enrollment saw greater long-term benefits with ublituximab than those with longer disease course.